Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840810 | 0.91 | CYP3A4 (0.49) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL19797951 | 0.91 | CYP3A4 (0.52) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL2842541 | 0.87 | CYP3A4 (0.45) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL18038582 | 0.87 | MEN1 (0.52) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL17464359 | 0.87 | CYP3A4 (0.45) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL2839079 | 0.86 | CYP3A4 (0.47) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL12940351 | 0.86 | CYP3A4 (0.51) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL1918575 | 0.85 | CYP3A4 (0.43) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL2841597 | 0.85 | CYP3A4 (0.44) | CYP3A4CYP2C8KCNH2CYP2C9CYP2C19 | |
| SCHEMBL2840735 | 0.85 | CYP3A4 (0.48) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022723-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022723-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | CYP3A4 640/4885CYP2C8 244/4885KCNH2 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.